CINCINNATI, June 19 /PRNewswire-FirstCall/ -- Kendle , a leading global full-service clinical research organization (CRO), today announced it has been added to the S&P SmallCap 600 Index. Kendle was added to the index after the close of trading June 7.
(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO )
“Kendle is honored to be added to the S&P SmallCap 600 index,” said Candace Kendle, PharmD, Chairman and Chief Executive Officer. “This recognition further validates our success in delivering results for our customers and shareholders.”
The S&P SmallCap 600 is maintained by the S&P Index Committee and includes selected U.S. companies with market capitalizations of $300 million-$1 billion. Criteria include financial viability, generally defined as four consecutive quarters of positive earnings; adequate liquidity and float; and a reasonable stock price. Introduced in 1994, the S&P SmallCap 600 is fast becoming the preferred small-cap index in the United States, covering approximately 3 percent of the domestic equities market. Along with the S&P 500 and the S&P MidCap 400, S&P SmallCap 600 companies are components of the S&P Composite 1500 index.
About Kendle
Kendle International Inc. is among the world’s leading global clinical research organizations. We deliver innovative and robust clinical development solutions - from first-in-human studies through market launch and surveillance - to help the world’s biopharmaceutical companies maximize product life cycles and grow market share. Our global clinical development business is focused on five regions - North America, Europe, Asia/Pacific, Latin America and Africa - to meet customer needs. We have conducted clinical trials or provided regulatory, pharmacovigilance and validation services in 70 countries.
In May 2006, Kendle announced the signing of a definitive agreement to acquire the Phase II-IV Clinical Services business of Charles River Laboratories International, Inc. , creating the world’s fourth largest provider of Phase II-IV clinical development services. The transaction is expected to close in the third quarter of 2006.
Additional information and investor kits are available upon request from Kendle, 1200 Carew Tower, 441 Vine Street, Cincinnati, OH 45202 or from the Company’s Web site at www.kendle.com.
Photo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comKendle International Inc.
CONTACT: Investors, Patty Frank, +1-513-763-1992, or Media, Lori Dorer,+1-513-345-1685, both of Kendle International Inc.
Web site: http://www.kendle.com/
